Company Overview of Survac ApS
Survac ApS focuses on the development of peptide based therapeutic cancer vaccines. It intends to offer the vaccine candidates for licensing and collaboration agreements. The company’s vaccine is being examined in clinical phase I/II trials. Survac ApS was founded in 2003 and is based in Hellerup, Denmark. As of January 6, 2006, Survac ApS operates as a subsidiary of Merck Group.
Founded in 2003
Key Executives for Survac ApS
Similar Private Companies By Industry
|7TM Pharma A/S||Europe|
|Acesion Pharma ApS||Europe|
|Action Pharma A/S||Europe|
|Adenium Biotech ApS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Survac ApS, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.